Latest news with #RoyaltyPharma
CNBC
a day ago
- Business
- CNBC
A bullish breakout in this little-known pharma stock is forming, charts show
Out of a universe of more than 10,000 tradable names, a strict technical screen we run at CappThesis recently surfaced just six stocks worth a closer look. One of them is Royalty Pharma (RPRX) , and we think the chart deserves our attention right now. There are four key reasons why RPRX stands out: 1. A bullish inverse head-and-shoulders pattern is nearing completion The first — and most importantly from our perspective — is a bullish inverse head-and-shoulders pattern has taken shape over the past several months. These patterns can mark a trend reversal or continuation of a trend. This particular formation has a combination of the two. The pattern has taken shape after a prolonged downtrend from the past few years. That said, the stock has been in rally-mode since bottoming in early December. The formation's neckline is near $34, and the stock is getting closer to challenging that level. A decisive breakout above that line would complete the pattern and trigger a breakout. The projected upside target based on the height of the formation is $39. That level also aligns with resistance from mid-2022. 2. Pattern forming above a larger base breakout What makes this setup even more compelling is that the inverse H & S pattern has been constructed above the breakout zone of a much larger base. The prior breakout occurred near $32, where rally attempts had been snuffed out multiple times since 2023. As the saying goes, once resistance is overtaken, it then becomes support, which is the case now. The ability of RPRX to hold above the prior breakout zone while forming a continuation pattern increases the probability of a sustained move higher. 3. Longer-term context supports the bull case Zooming out, RPRX still has plenty of ground to recover. The stock reached a high of $56.50 shortly after its IPO in mid-2020. Since then, it's been in a multiyear downtrend before bottoming out in late 2024. That prolonged decline may have caused previously eager buyers to become disinterested. This is understandable given how well so many other stocks have done the last two years. However, the sell-off helped reset expectations, valuations, and sentiment—creating a potential springboard if this pattern can be leveraged. Further, the 38.2% Fibonacci retracement of the entire decline from 2020 through 2023 is near $33. That lines up with the 32-breakout zone discussed above, making this area even more important to potentially overtake. 4. Relative strength From a relative strength perspective, RPRX has been outperforming many other biotech counterparts. We can see this via the relative strength line vs. the XBI ETF. Thus, the comeback is evident both on an absolute basis and relative to RPRX's peers, which of course is constructive for further gains as well. The bottom line is that RPRX has done a good job bouncing from its lows, and for that to develop into a more substantial and long-term uptrend, the stock must continue to form and break out from bullish chart formations. It has a chance to continue that process now. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
05-06-2025
- Business
- Yahoo
Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors
BOSTON and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointments of Adam Koppel and Christopher Hite to its Board of Directors. 'We are thrilled to welcome Adam and Chris to our Board of Directors. Their extensive track records as respected advisors to biopharma companies on corporate and financial strategy will be incredibly valuable as we continue to execute on our mission to advance next-generation therapies for the treatment of obesity,' said Ron Renaud, President and Chief Executive Officer, Kailera. 'It's an exciting time to join Kailera's Board as they progress their pipeline toward late-stage global trials, and I look forward to contributing to the company's continued success and long-term value creation,' said Dr. Koppel. Mr. Hite added, 'I am pleased to join the Board of Kailera at this important time of innovation in the obesity space that has positively impacted millions of patients worldwide. Kailera has a clear strategy to advance their diversified pipeline, and I look forward to supporting the leadership team as they work towards achieving their mission.' Dr. Koppel is a distinguished investor and strategic leader with more than 25 years of biopharmaceutical industry experience. He is a Partner on Bain Capital's Life Sciences team and initially joined Bain Capital in 2003. Previously, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He currently sits on the Board of Directors of Areteia Therapeutics and Cardurion Pharmaceuticals and serves on the Board of Trustees at Newton Wellesley Hospital. Dr. Koppel also co-chairs the Harvard Medical School Discovery Council and serves on the Mass General Brigham Innovation Growth Board. He received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. Dr. Koppel also received an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar, and graduated magna cum laude from Harvard University with an A.B. and A.M. in History and Science. Mr. Hite, a seasoned financial executive with over 25 years of financial and strategic experience in the biopharmaceutical industry, will serve as an independent board member and audit committee chair. Mr. Hite currently serves as Executive Vice President and Vice Chairman at Royalty Pharma. Prior to joining Royalty Pharma in 2020, he was at Citibank for over a decade, serving most recently as Vice Chairman of Banking, Capital Markets and Advisory (BCMA) and a member of the BCMA Executive Committee, and previously as the Global Head of Healthcare Investment Banking. Prior to joining Citibank, Mr. Hite was the Global Head of Healthcare Investment Banking at Lehman Brothers. He serves on the Board of Trustees at Lehigh University, the Board of Advisors of Faster Cures, a center of the Milken Institute, and served on the Board of Directors of Acceleron Pharma Inc. until its acquisition by Merck in November 2021. Mr. Hite has a B.S. from Lehigh University, and a J.D. and M.B.A. from the University of Pittsburgh. About Kailera Therapeutics Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit and follow us on LinkedIn and X. Contact Information Maura Gavaghan Vice President, Corporate Communications and Investor Relations while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ('RP Management'). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. 'The completion of the internalization marks an exciting new chapter for Royalty Pharma,' said Pablo Legorreta, founder and Chief Executive Officer. 'It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences industry.' This transaction represents a significant milestone in Royalty Pharma's evolution and is expected to enhance long-term shareholder value through a simplified corporate structure, strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments. The company will update its full-year 2025 guidance to reflect the internalization when it reports its second quarter 2025 financial results. Background on the Manager Since its founding in 1996, Royalty Pharma had operated under an external management model, relying on a separate Manager, owned by Pablo Legorreta and other members of senior management, for all operations and personnel. The company paid quarterly fees to the Manager equal to 6.5% of Portfolio Receipts and 0.25% of the value of security investments. Following the closing of the internalization transaction, Royalty Pharma is no longer externally managed, and all employees of the Manager have become employees of Royalty Pharma. Prior to 2024, Pablo Legorreta was the sole owner of the Manager. In early 2024, equity interests in the Manager were granted to 35 team members to support long-term succession planning and enhance alignment; these shares will vest over 10 years. Management (excluding Pablo Legorreta) will receive approximately 50% of the equity issued in the transaction, which will continue to vest through 2033. Pablo Legorreta agreed to have his equity vest over five years, despite no prior vesting requirement. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute 'forward-looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities, market growth, and plans for capital deployment, plus the benefits of the internalization transaction, including cash savings, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as 'may,' 'might,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'target,' 'forecast,' 'guidance,' 'goal,' 'predicts,' 'project,' 'potential' or 'continue,' the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements, including because the internalization transaction is subject to shareholder approval. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference Royalty Pharma's reports and documents filed with the U.S. Securities and Exchange Commission ('SEC') by visiting EDGAR on the SEC's website at Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PT RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET The webcasts will be accessible from Royalty Pharma's 'Events' page at Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit Royalty Pharma Investor Relations and Communications +1 (212) 883-6772ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street's revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share increased from $0.01 in the same quarter last year. Is now the time to buy Royalty Pharma? Find out in our full research report. Revenue: $568 million vs analyst estimates of $570 million (flat year on year, in line) Adjusted EBITDA: $738 million vs analyst estimates of $703.4 million (130% margin, 4.9% beat) Operating Margin: 94%, up from -13% in the same quarter last year Free Cash Flow Margin: 105%, up from 102% in the same quarter last year Market Capitalization: $14.19 billion 'Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance,' said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself. A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Royalty Pharma's sales grew at a tepid 3.8% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a tough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Royalty Pharma's performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 2% annually. We can dig further into the company's revenue dynamics by analyzing its most important segment, Portfolio Receipts. Over the last two years, Royalty Pharma's Portfolio Receipts revenue averaged 11.2% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Royalty Pharma's $568 million of revenue was flat year on year and in line with Wall Street's estimates. We also like to judge companies based on their projected revenue growth, but not enough Wall Street analysts cover the company for it to have reliable consensus estimates. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Royalty Pharma has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average operating margin of 55.5%. Looking at the trend in its profitability, Royalty Pharma's operating margin rose by 17.3 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 60 percentage points on a two-year basis. This quarter, Royalty Pharma generated an operating profit margin of 94%, up 107 percentage points year on year. This increase was a welcome development and shows it was more efficient. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Sadly for Royalty Pharma, its EPS declined by 10.5% annually over the last five years while its revenue grew by 3.8%. However, its operating margin actually expanded during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings. We can take a deeper look into Royalty Pharma's earnings to better understand the drivers of its performance. Royalty Pharma recently raised equity capital, and in the process, grew its share count by 63.3% over the last five years. This has resulted in muted earnings per share growth but doesn't tell us as much about its future. We prefer to look at operating and free cash flow margins in these situations. In Q1, Royalty Pharma reported EPS at $0.75, up from $0.01 in the same quarter last year. We also like to analyze expected EPS growth based on Wall Street analysts' consensus projections, but there is insufficient data. Revenue was in line but EBITDA beat on better profitability. Overall, the quarter was solid. The stock traded up 1.4% to $33.25 immediately following the results. Is Royalty Pharma an attractive investment opportunity right now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
